Sibylla Biotech

Sibylla Biotech S.p.A. is a preclinical-stage biotechnology company based in Verona, Italy, founded in 2017. The company specializes in early-stage drug discovery, focusing on small molecule degraders that target undruggable proteins through its proprietary PPI-FIT platform. This innovative technology utilizes molecular simulations and AI to identify small molecules that can degrade proteins in their transient, intermediate folding states.

Sibylla Biotech is advancing its lead candidate, which targets Cyclin D1, a protein associated with various cancers, into the preclinical phase. The company also has a pipeline that includes targets like KRAS, which is linked to several types of cancer. Sibylla has established a research collaboration with MD Anderson Cancer Center and is actively seeking additional partnerships to further its drug development efforts. The company raised €23 million in a Series A funding round in October 2022, marking a significant milestone in its growth.